Publikationen, an denen er mitarbeitet Germán Bou Arévalo (9)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  2. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

    Infection

2021

  1. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1631-1637

2020

  1. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

    The Lancet, Vol. 396, Núm. 10250, pp. 535-544

  2. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

2017

  1. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

2013

  1. Epidemiological and clinical complexity of amoxicillin-clavulanate- resistant Escherichia coli

    Journal of Clinical Microbiology, Vol. 51, Núm. 7, pp. 2414-2417

2012

  1. Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 7, pp. 3576-3581